This is a paid press release. Contact the press release distributor directly with any inquiries.

AAV for the Hereditary Retinal Diseases Competitive Landscape Report 2026: Comprehensive Insights About 75+ Companies and 80+ Drugs

Research and Markets

Thu, February 19, 2026 at 12:38 AM GMT+9 4 min read

Company Logo

Key market opportunities lie in AAV gene therapy advancements for hereditary retinal diseases. Future prospects include combination with CRISPR for precise genome editing, novel delivery platforms, and strategies to bypass immune responses, expanding treatment scope and patient eligibility while addressing current challenges in gene size delivery, immune response, and cell targeting.

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) – The “AAV for the Hereditary Retinal Diseases - Competitive Landscape, 2026” has been added to ** ResearchAndMarkets.com’s** offering.

The report offers a thorough analysis of over 75 companies and 80 drugs in the Adeno-Associated Virus (AAV) arena concerning hereditary retinal conditions. This study provides insights into therapeutic assessments by product type, stage, route, and molecule type, and also reviews inactive pipeline products globally.

AAV in Retinal Gene Therapy

Adeno-associated virus (AAV) vectors have emerged as versatile gene therapy vehicles for hereditary retinal diseases, attributed to genetic mutations affecting retinal function. These mutations manifest in conditions like Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa, and Choroideremia, causing progressive vision loss. The AAV vectors offer localized delivery with reduced systemic exposure and render low immunogenic responses, enabling long-term expression in retinal cells.

The evolution of AAV gene therapy includes coupling AAV with CRISPR/Cas9 for precise genome editing. Other advances like dual AAV vectors and novel delivery systems aim to enhance gene therapy’s reach for large genetic payloads. Broad-spectrum approaches, including neuroprotective treatments, offer prospects beyond mutation specificity.

Challenges and Future Prospects

While promising, challenges such as limited packaging capacity of AAV vectors (~4.7 kb) constrain large gene delivery. Immune responses, especially pre-existing neutralizing antibodies, can hinder re-administration and efficacy. Efficient targeting of retinal cells poses additional hurdles, especially for less invasive routes. Manufacturing at scale remains complex and cost-intensive, impacting widespread clinical adoption.

Recent Developments in AAV Gene Therapy

In May 2025, Ocugen received FDA rare pediatric disease designation for OCU410ST, targeting ABCA4-associated retinopathies.

In April 2025, Atsena Therapeutics' ATSN-201 earned FDA Regenerative Medicine Advanced Therapy designation for X-linked retinoschisis.

In March 2025, SpliceBio initiated Phase I/II trials for SB-007, addressing Stargardt disease.

ViGeneron GmbH began a Phase I/II study of VG801 targeting Stargardt disease in December 2024.

Opus Genetics gained RPD designation for OPGx-LCA5, focusing on Leber congenital amaurosis in August 2024.

 






Story Continues  

Industry Leaders and Innovations

Noteworthy players in this sector include Novartis, MeiraGTx, and Beacon Therapeutics, among others. Novartis offers LUXTURNA, a gene therapy for RPE65 mutation-related retinal dystrophy. MeiraGTx’s botaretigene sparoparvovec addresses X-linked retinitis pigmentosa, while Beacon’s AGTC-501 advances treatments for similar conditions.

Competing entities are continuously striving for breakthroughs. 4D Molecular Therapeutics explores innovative vectors for gene delivery, and Coave Therapeutics focuses on prevalent neurodegenerative and ocular diseases. Together, these organizations are propelling genetic therapies toward more extensive treatments.

Conclusion

The report underscores significant advancements and potential challenges in AAV-based gene therapies for hereditary retinal diseases. Despite obstacles, the growing pipeline and ongoing research promise a transformative impact on treatment landscapes, aiming for inclusivity and effectiveness.

Key Topics Covered:

Introduction

Executive Summary

AAV for the hereditary retinal disease: Overview

Introduction

Types of hereditary retinal diseases

Mechanism of action

Challenges and Limitation

Future directions in AAV gene therapy

AAV for the hereditary retinal disease - Analytical Perspective: In-depth Commercial Assessment

AAV for the hereditary retinal disease Collaboration Analysis by Companies

Competitive Landscape

Comparative Assessment of Companies (by therapy, development stage, and technology)

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

AAV for the hereditary retinal disease: Company and Product Profiles (Marketed Therapies)

Novartis

Company Overview

LUXTURNA

Product Description

Research and Development Activities

Product Developmental Activities

AAV for the hereditary retinal disease: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

Comparative Analysis

Johnson & Johnson/MeiraGTx

Company Overview

Botaretigene sparoparvovec

Product Description

Research and Development Activities

Product Developmental Activities

Mid Stage Products (Phase II)

Comparative Analysis

Beacon Therapeutics

Company Overview

AGTC-501

Product Description

Research and Development Activities

Product Developmental Activities

Early Stage Products (Phase I)

Comparative Analysis

4D Molecular Therapeutics

Company Overview

4D 125

Product Description

Research and Development Activities

Product Developmental Activities

Preclinical and Discovery Stage Products

Comparative Analysis

MeiraGTx

Company Overview

A007

Product Description

Research and Development Activities

Product Developmental Activities

Inactive Products

Comparative Analysis

AAV for the hereditary retinal disease- Unmet needs

AAV for the hereditary retinal disease - Market drivers and barriers

Appendix

Companies Featured

Novartis

MeiraGTx Limited. A

Johnson & Johnson

Neurophth Therapeutics

Beacon Therapeutics

4D Molecular Therapeutics

Coave Therapeutics

MeiraGTx Limited. A

Ocugen

Atsena Therapeutics

SpliceBio

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Terms and Privacy Policy

Privacy Dashboard

More Info